Palatin Technologies Inc New (PTN) Options

They are looking for a partner to help finance on going studies and partnership which is good so we don't dilute anymore

Had good news today and tk is down at .61

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Over 6 million traded in one day and I can barely buy 15000 shares  every 1 hour is bullshit

$PTN: Added 10k here at $0.82

On that dip from $1.14

Letsssssss goooooooooooooooooooooooooooo

GO $PTN

 Betting on tomorrow or Wednesday 

Ptn got new orphan drug approval. Will see what happens news coming

Sitting tight until next week

Results have to be this week.

Today or tomorrow maybe

Outcome data by the end of the month per ceo 

3 drugs coming out the end of there pipeline

this Stock is on the move!!! finished Obesity drug study today, results will be released by end of this qquarter. price target $17. no brainer. flying under the radar......

PTN .94 +9% ...19m float...

HC Wainwright Reaffirms “Buy” Rating for Palatin Technologies (NYSEAMERICAN:PTN)



Posted by MarketBeat News on Jan 30th, 2025





Share on Twitter Share on Facebook Share on LinkedIn

Share on Stocktwits





?Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $17.00 price objective on the biopharmaceutical company’s stock.

Palatin Technologies Trading Up 0.7 %

NYSEAMERICAN PTN opened at $0.91 on Tuesday. Palatin Technologies has a 1-year low of $0.68 and a 1-year high of $5.22. The stock has a market capitalization of $17.77 million, a PE ratio of -0.46 and a beta of 0.90.

Get Palatin Technologies alerts:

Institutional Trading of Palatin Technologies

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in shares of Palatin Technologies in the third quarter valued at $51,000. HB Wealth Management LLC lifted its holdings in Palatin Technologies by 86.3% in the 4th quarter. HB Wealth Management LLC now owns 110,500 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 51,200 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Palatin Technologies in the 2nd quarter worth $29,000. 11.50% of the stock is currently owned by institutional investors and hedge funds.

Nice level to buy some

Still nothing going on with ceo news

I don't think she is going to stop this time 

Need a company that's going to sell this product 

Nice results 

Hc wainwright 17$ price target was 75$ still a ways off of these 2 prices but 2 months will see

Can't buy big chipmunks of it

News any time

Meibo eye drops just came out for dry eyes saw commercial 

Far off from 17$ though

Looking good

Let hear about a partnership

Let’s go Merck or Pfizer

Got mine

Loaded thanks for the share price let’s see what happens in the next 6 months

Last of the cheapies

Wainwright really confident the stock going to see 17$ can’t wait

Bottom shot until partners get established

I guess it’s the atm for the company or eye drug not approved will see on the first

I bought this many shares yesterday

Maybe some seller didn’t put a limit on his sell. He won’t do that again

Not as easy to get today

Cat must be out of the bag

PTN under $2

I got enough for the ride

Time to load up

PTN under $2

PTN under $2

You may just get your wish. This stock has been making promises for years and now expects everyone to wait until 2025 for any hope of marketing its dry eye ointment, while looking for a partner to do the heavy lifting. Ahhhhhhh..........

PTN Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

https://finance.yahoo.com/news/palatin-announces-phase-3-pl9643-113000533.html

Waiting for 1.25

PTN under $2

Well just great. Pump it the few days before the announcement and sell it on the news.

I love the way these low cap stocks move up and down on no news.

On the move with high volume. Hope something announced soon.

So I guess people are disappointed with the latest report. Nothing new but nothing detrimental either.